19837762

Source:http://linkedlifedata.com/resource/pubmed/id/19837762

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003250, umls-concept:C0008109, umls-concept:C0034603, umls-concept:C0278996, umls-concept:C1516213
pubmed:issue	11
pubmed:dateCreated	2009-10-30
pubmed:abstractText	Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy. For this purpose, the long-lived positron emitter (89)Zr (half-life, 78.4 h) recently became available. The aim of the present first-in-humans (89)Zr immuno-PET study was to assess safety, biodistribution, radiation dose, and quantification of the (89)Zr-labeled chimeric monoclonal antibody (cmAb) U36 in patients with head and neck squamous cell carcinoma (HNSCC). In addition, the performance of immuno-PET for detecting lymph node metastases was evaluated, as described previously.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0217410
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Radioisotopes, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Zirconium
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1535-5667
pubmed:author	pubmed-author:BörjessonPontus K EPK, pubmed-author:BoellaardRonaldR, pubmed-author:CastelijnsJonas AJA, pubmed-author:JauwYvonne W SYW, pubmed-author:LeemansC RenéCR, pubmed-author:RoosJan CJC, pubmed-author:de BreeRemcoR, pubmed-author:van DongenGuus A M SGA
pubmed:issnType	Electronic
pubmed:volume	50
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1828-36
pubmed:meshHeading	pubmed-meshheading:19837762-Aged, pubmed-meshheading:19837762-Antibodies, Monoclonal, pubmed-meshheading:19837762-Bone Marrow, pubmed-meshheading:19837762-Carcinoma, Squamous Cell, pubmed-meshheading:19837762-Clinical Trials as Topic, pubmed-meshheading:19837762-Drug Toxicity, pubmed-meshheading:19837762-Female, pubmed-meshheading:19837762-Head and Neck Neoplasms, pubmed-meshheading:19837762-Humans, pubmed-meshheading:19837762-Isotope Labeling, pubmed-meshheading:19837762-Male, pubmed-meshheading:19837762-Middle Aged, pubmed-meshheading:19837762-Positron-Emission Tomography, pubmed-meshheading:19837762-Radiation Dosage, pubmed-meshheading:19837762-Radioisotopes, pubmed-meshheading:19837762-Radiometry, pubmed-meshheading:19837762-Recombinant Fusion Proteins, pubmed-meshheading:19837762-Tissue Distribution, pubmed-meshheading:19837762-Zirconium
pubmed:year	2009
pubmed:articleTitle	Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
pubmed:affiliation	Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't